Skip to main content

Table 5. Summary of reported patients who exhibited thyroiditis and isolated adrenocorticotropic hormone deficiency in association with cancer treatment with nivolumab

From: Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature

Ref. Age/sex Nivolumab Thyroiditis IAD Other IRAEs
Target cancer Regimen Administration times (courses) Time from first nivolumab administration to thyroiditis onset (months) Thyroid function abnormality Thyroid autoantibodies Abnormality on thyroid ultrasonography Time from first nivolumab administration to IAD onset (months) Major symptoms Pituitary autoantibodies Morphological abnormality in the pituitary on MRI
[15] 60/M LAC 3 mg/kg every 2 weeks 11 5 Hypothyroidism N/D N/D 7 Fatigue, anorexia, dizziness, gait instability N/D None None
[16] 54/M RCC 2 mg/kg every 2 weeks 12 3 Hypothyroidism Positive (TgAb and TPOAb) N/D 6 Fatigue, hypoglycemia N/D None None
[19] 58/M Melanoma 3 mg/kg every 2 weeks N/D 4 Transient thyrotoxicosis and subsequent hypothyroidism Positive (TgAb) N/D 8 Fatigue, anorexia, weakness N/D None Hypercalcemia
[20] 63/F Melanoma 2 mg/kg every 3 weeks 8 6 Transient thyrotoxicosis and subsequent hypothyroidism Positive (TgAb) Low echogenicity 8 Fatigue N/D None None
Present case 69/F LAC 3 mg/kg every 2 weeks 6 2 Transient thyrotoxicosis and subsequent hypothyroidism Negative Low echogenicity 7 Fatigue, anorexia, weakness Negative Atrophy None
  1. F female, IAD isolated adrenocorticotropic hormone deficiency, IRAE immune-related adverse event, LAC lung adenocarcinoma, M male, MRI magnetic resonance imaging, N/D not described, RCC renal cell carcinoma, TgAb thyroglobulin autoantibody, TPOAb thyroid peroxidase autoantibody